# Hematopoietic Malignancies Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $79,592

## Abstract

Hematopoietic Malignancies Program: Summary
The mission of the Hematopoietic Malignancies (HE) Program is to improve the outcome of patients with
leukemia, lymphoma, and multiple myeloma through basic and translational laboratory studies and clinical
investigation. The HE Program has established a highly interactive transdisciplinary approach that includes
efforts directed at: (1) genetic discovery; (2) modeling hematopoietic malignancy-associated genetic lesions;
(3) characterizing signal transduction pathways that are crucial for cellular growth control and are perturbed in
hematologic cancers; (4) testing experimental therapeutics with molecular analysis to ascertain mechanisms of
drug action and drug resistance; (5) defining genetic and environmental risk factors that contribute to the
development of hematologic cancers; and (6) translation of these findings into novel therapeutic approaches
for leukemia, lymphoma, and multiple myeloma patients. This research is conducted across three unifying
themes:
Theme 1: Gaining a Greater Understanding of the Molecular Pathogenesis of Hematopoietic Malignancies
Theme 2: Undertaking Translational Studies to Identify, Develop, and Optimize Treatment Options for Patients
with Hematopoietic Malignancies
Theme 3: Advancing Therapeutic Interventions and Understanding Risk Factors to Improve Outcomes in
Patients with Hematopoietic Malignancies
HE Program: Key Metrics
Membership (7 departments, 2 schools) 26
Full 17
Associate 9
Cancer-relevant Funding (direct costs as of
$9,433,185
05/31/2017)
NCI $2,481,966 26%
Peer-reviewed $2,725,651 29%
Non-peer-reviewed $4,225,568 45%
Cancer-relevant Publications (1/2012-7/2017) 301
Inter-programmatic 79 26%
Intra-Programmatic 68 23%
High-Impact 139 46%
Accruals to Clinical Trials (2016) 134 37
Therapeutic 78 25
Other Interventional 9 1
Non-interventional 47 11

## Key facts

- **NIH application ID:** 9965774
- **Project number:** 5P30CA082103-21
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** Neil P Shah
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $79,592
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9965774

## Citation

> US National Institutes of Health, RePORTER application 9965774, Hematopoietic Malignancies Program (5P30CA082103-21). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/9965774. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*